Allurion Technologies (NYSE:ALUR – Get Free Report) and Aurora Cannabis (NASDAQ:ACB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Insider and Institutional Ownership
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Allurion Technologies and Aurora Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allurion Technologies | -199.96% | N/A | -77.13% |
| Aurora Cannabis | -15.96% | -0.58% | -0.42% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allurion Technologies | $17.21 million | 1.00 | -$7.20 million | ($10.56) | -0.18 |
| Aurora Cannabis | $367.13 million | 0.65 | $1.63 million | ($0.69) | -6.14 |
Aurora Cannabis has higher revenue and earnings than Allurion Technologies. Aurora Cannabis is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Allurion Technologies and Aurora Cannabis, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allurion Technologies | 1 | 2 | 1 | 0 | 2.00 |
| Aurora Cannabis | 1 | 1 | 0 | 1 | 2.33 |
Allurion Technologies currently has a consensus target price of $9.25, indicating a potential upside of 395.98%. Given Allurion Technologies’ higher possible upside, research analysts clearly believe Allurion Technologies is more favorable than Aurora Cannabis.
Volatility and Risk
Allurion Technologies has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
Summary
Aurora Cannabis beats Allurion Technologies on 9 of the 15 factors compared between the two stocks.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
About Aurora Cannabis
Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
